Opportunity
CanadaBuys #1000273182
Health Canada Solicitation for Laboratory Measurement of UV Filters in Biobanked Urine Samples
Posted
September 17, 2026
Respond By
October 01, 2026
Identifier
1000273182
NAICS
541380
Health Canada is seeking laboratory services to measure urinary concentrations of eight ultraviolet (UV) filter compounds in biobanked urine samples from children aged 7-12 years, supporting biosurveillance and risk assessment efforts. - Government Buyer: - Health Canada (Department of Health) - Contact: Wesley Phillips - OEMs and Vendors: - No specific commercial OEMs are named; the University of Alberta Centre for Toxicology is referenced as the only lab meeting essential requirements - Products/Services Requested: - Measurement of urinary concentrations of eight UV filter compounds: - N-methyl-p-aminobenzoic acid (4-MABA) - N,N-dimethyl-p-aminobenzoic acid (4-DMABA) - Benzophenone-1 (BP-1) - Benzophenone-3 (BP-3) - Benzophenone-12 (BP-12) - 4-hydroxybenzophenone (4-OHBP) - Octocrylene metabolite - Hexyl-2-[4-(diethylamino)-2-hydroxybenzol] benzoate (DHHB) - Laboratory analysis and biosurveillance data generation for urine samples from the MIREC Biobank and MIREC-ENDO study - Unique or Notable Requirements: - Contractor must be ISO 17025 accredited and participate in recognized proficiency/quality regimes (e.g., CALA) - All samples must remain in Canada throughout the process - Data must be suitable for federal decision-making and scientific publication - Estimated contract value: up to $190,000 CAD - Contract duration: 30 months, with two one-year option periods
Description
This solicitation seeks the measurement of urinary concentrations of eight ultraviolet (UV) filter compounds in urine samples from the MIREC Biobank, focusing on children aged 7-12 years. The project aims to fill gaps in biomonitoring data for UV filters, which are chemicals used in personal care products and plastics that may have endocrine-disrupting effects. The contractor must be ISO accredited and participate in proficiency/quality regimes, with samples remaining in Canada. The contract duration is 30 months, and the work supports Health Canada's risk assessments and scientific literature.